Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Using synthetic lethality to find effective combination therapies for cancer
René Bernards
Netherlands Cancer Inst., Amsterdam, Netherlands
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Mechanisms of resistance to RAF/MEK inhibitors
David B. Solit
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Overcoming acquired resistance to first-generation kinase inhibitors in lung cancer
William Pao
Vanderbilt Univ., Nashville, TN, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies
Mechanisms of acquired resistance to ALK/ROS1 inhibitors
Alice T. Shaw
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from 2013 Molecular Targets and Cancer Therapeutics conference on October 20, 2013 10:30 AM-12:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4